BLRX BioLineRx Ltd: רווח למניה ב-12 החודשים האחרונים

Aphexda sales dynamics and the development of the oncology portfolio influence the percentage growth history of EPS YoY (ttm), where 55.10 indicates the level of this metric for BioLineRx Ltd. (BLRX). Financial stability is based on the commercialization of approved drugs. Simultaneously, software robots are being implemented to accelerate data validation. This chart helps assess the stability of earnings per share, eliminating the risks of overpaying for the asset.

This indicator measures the rolling annual growth rate of net earnings per share, smoothing out short-term fluctuations to identify the long-term profitability trend. By analyzing the rolling annual EPS YoY dynamics, an investor assesses the efficiency of BioLineRx Ltd. (BLRX) R&D expenditures in retaining leading oncologists through option programs and the capitalization of their scientific achievements.